Pulmicort Generics Win a Negative for Teva, Canaccord Says
Stock Chart for Teva Pharmaceutical Industries Ltd (TEVA)
U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e- mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt **NOTE: AstraZeneca May Appeal U.S. Patent Ruling on Pulmicort Respules NSN MKMET76JTSEN <GO>
To contact the editor responsible for this story: Emma O’Brien at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.